The University of Chicago Header Logo

Connection

Steven Chmura to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Steven Chmura has written about Treatment Outcome.
Steven Chmura
Connection Strength
0.464
Treatment Outcome
  1. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.077
  2. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.065
  3. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.058
  4. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.049
  5. Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
    View in: PubMed
    Score: 0.038
  6. Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
    View in: PubMed
    Score: 0.024
  7. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.021
  8. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.019
  9. NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
    View in: PubMed
    Score: 0.019
  10. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.017
  11. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):161-166.
    View in: PubMed
    Score: 0.015
  12. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan; 126(2):309-16.
    View in: PubMed
    Score: 0.014
  13. Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys. 2014 Mar 06; 15(2):4547.
    View in: PubMed
    Score: 0.012
  14. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.011
  15. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
    View in: PubMed
    Score: 0.011
  16. Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. Br J Radiol. 2006 Jun; 79(942):497-503.
    View in: PubMed
    Score: 0.007
  17. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.